J. Vansteenkiste

发表

Ceritinib in ALK-rearranged non-small-cell lung cancer.

J. Engelman, Michael Thomas, A. Shaw, 2014, The New England journal of medicine.

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

E. Van Cutsem, J. Tabernero, L. Paz-Ares, 2014, Clinical Cancer Research.

Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.

J Bogaert, K. Nackaerts, J. Bogaert, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Lucio Crinò, Carlos Barrios, Johan Vansteenkiste, 2013, The Lancet. Oncology.

An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates.

Huanming Yang, Jian Wang, L. Bolund, 2020, Cancer cell.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Masahiro Tsuboi, Iver Petersen, Hisao Asamura, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET.

Johan Nuyts, Otto S Hoekstra, Adriaan A Lammertsma, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, A. Nicholson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phenotype molding of stromal cells in the lung tumor microenvironment

P. Carmeliet, S. Aerts, D. Lambrechts, 2018, Nature Medicine.

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018, The New England journal of medicine.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

C. Gridelli, S. Thongprasert, E. Felip, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S Senan, K. Kerr, S. Novello, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Prasad Adusumilli, Young Tae Kim, Ugo Pastorino, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M. Oudkerk, P. Postmus, K. Kerr, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer

Hisao Asamura, Kari Chansky, J. Crowley, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Bart Spiessens, Benjamin Dizier, Stefan Suciu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up.

J. Vansteenkiste, M. Demedts, P. D. De Leyn, 2001, Lung cancer.

Chapter 2 – PET Imaging

C. Dooms, J. Vansteenkiste, J. Wynants, 2008 .

Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment.

J. Vansteenkiste, M. Demedts, M. Thomeer, 2004, Respiratory medicine.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Masahiro Fukuoka, Yutaka Nishiwaki, Danny Rischin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.

P. Dupont, L. Mortelmans, J. Vansteenkiste, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer

Gerald J. Kutcher, Sigrid Stroobants, Dominique Huyskens, 2000 .

18 fluoro-2-deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy in stage IIIA-N2 NSCLC: a multi-center prospective study

K. Nackaerts, L. Mortelmans, A. Lammertsma, 2001 .

Prognostic value of fluorodeoxyglucose uptake in non-small cell lung cancer: time for standardization and validation.

C. Dooms, J. Vansteenkiste, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.

Otto S Hoekstra, Adriaan A Lammertsma, Johan Vansteenkiste, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

M. Zauderer, J. Schellens, D. Fennell, 2019, Investigational New Drugs.

Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.

J. Vansteenkiste, E. Moon, S. Antonia, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Ying Cheng, E. Cho, S. Ramalingam, 2019, Clinical Cancer Research.

21 – Positron Emission Tomography

C. Dooms, J. Vansteenkiste, C. Deroose, 2012 .

The multidisciplinarity of stage III non-small cell lung cancer.

C. Dooms, J. Vansteenkiste, P. D. De Leyn, 2009, European journal of cancer.

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Keunchil Park, J. Mazières, J. Vansteenkiste, 2015 .

Second-Line Treatment of Advanced Non-small Cell Lung Cancer

N. Hanna, C. Gridelli, J. Heymach, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience.

J. Vansteenkiste, M. Demedts, P. D. De Leyn, 2004, Lung cancer.

14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)

J. Yi, J. Mazières, J. Vansteenkiste, 2015 .

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer

J. Crowley, V. Rusch, M. Tsuboi, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Staging of lung cancer.

C. Dooms, J. Vansteenkiste, S. Stroobants, 2007, Radiologic clinics of North America.

Staging of lung cancer.

C. Dooms, J. Vansteenkiste, S. Stroobants, 2007, Radiologic clinics of North America.

Chemotherapy-induced anemia: the story of darbepoetin alfa

J. Vansteenkiste, S. Elliott, J. Glaspy, 2013, Current medical research and opinion.

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.

J. Crawford, R. Pirker, J. Vansteenkiste, 2012, Lung cancer.

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

C. Bokemeyer, P. Gascón, J. Vansteenkiste, 2009, BMC Cancer.

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

R. Ramlau, R. Pirker, J. Vansteenkiste, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current status of immune checkpoint inhibition in early stage NSCLC.

D. de Ruysscher, D. Ruysscher, S. Peters, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

J. Canon, R. Pirker, J. Vansteenkiste, 2005, Investigational New Drugs.

Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.

M. Ahn, Yi-long Wu, E. Felip, 2014 .

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

C. Rudin, P. V. Van Schil, D. de Ruysscher, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC.

J. Vansteenkiste, E. Wauters, I. Vanden Bempt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymph node mapping in non-small cell lung cancer with FDG-PET scan: a prospective study in 690 LN levels from 68 patients

K. Nackaerts, J. Bogaert, P. Dupont, 1997 .

Selective mediastinal node irradiation in non-small cell lung cancer in the IMRT/VMAT era: How to use E(B)US-NA information in addition to PET-CT for delineation?

C. Dooms, K. Nackaerts, D. de Ruysscher, 2016, Radiotherapy and Oncology.

Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment: evidence-based staging.

C. Dooms, J. Vansteenkiste, P. D. De Leyn, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Imaging for staging stage III nonsmall cell lung cancer

C. Dooms, J. Vansteenkiste, H. Becker, 2007 .

Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lu

K. Nackaerts, L. Mortelmans, J. Vansteenkiste, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N 2 Non – Small-Cell Lung Cancer : A Leuve

K. Nackaerts, L. Mortelmans, J. Vansteenkiste, 2006 .

Improving patient management in metastatic non-small cell lung cancer.

J. Vansteenkiste, 2007, Lung cancer.

What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.

J. Vansteenkiste, C. Ziske, J. Lester, 2013, Lung cancer.

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

H. Groen, G. Scagliotti, N. Hanna, 2022, European journal of cancer.

Pulmonary Biopsies via Thoracoscopy

C. Dooms, J. Vansteenkiste, 2014 .

The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

Fergus Gleeson, Heber MacMahon, Jin Mo Goo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Chih-Hsin Yang, F. de Marinis, J. Wolf, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological Correlates of the Maximum 18-Fluoro-2-Deoxy-Glucose Uptake on Positron Emission Tomography in Non-small Cell Lung Carcinoma after Induction Chemotherapy

C. Dooms, J. Vansteenkiste, E. Verbeken, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact and Safety of Adjuvant Chemotherapy on Pulmonary Function in Early Stage Non-Small Cell Lung Cancer

N. Reinmuth, I. Zuna, Michael Thomas, 2013, Respiration.

Unexpected slight fluorodeoxyglucose-uptake on positron emission tomography in a pulmonary hamartoma.

J. Vansteenkiste, C. Deroose, E. Verbeken, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Quantification of radiation-induced lung damage with CT scans: The possible benefit for radiogenomics

R. Jeraj, W. V. van Elmpt, D. de Ruysscher, 2013, Acta oncologica.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Keunchil Park, N. Rizvi, J. Mazières, 2018, The Lancet. Oncology.

Low-dose CT screening for lung cancer: trial and error?

K. Nackaerts, J. Vansteenkiste, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Three‐Year Follow‐Up of a Randomized Phase II Trial on Refinement of Early‐Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)

C. Schumann, Michael Thomas, M. Kreuter, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non–Small-Cell Lung Cancer

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.

C. Dooms, J. Vansteenkiste, P. D. De Leyn, 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer.

G. Scagliotti, P. Rocmans, H. Pass, 2003, Lung cancer.

1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

N. Altorki, P. Therasse, T. Mitsudomi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

T. Gorlia, A. Dingemans, E. Felip, 2022, Scientific Reports.

Immunotherapy in unresectable stage III non-small cell lung cancer: state of the art and novel therapeutic approaches.

D. de Ruysscher, J. Vansteenkiste, B. Reymen, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature

C. Dooms, K. Nackaerts, B. Weynand, 2022, EJNMMI Research.

The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

O. Hoekstra, E. Smit, F. Schramel, 2003, Lung cancer.

Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature.

J. Vansteenkiste, M. Demedts, P. D. De Leyn, 1998, Lung cancer.

The Future in Diagnosis and Staging of Lung Cancer: Introduction

J. Vansteenkiste, 2006, Respiration.

Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III‐N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes

C. Dooms, D. de Ruysscher, P. Bulens, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunotherapy for lung cancer : ongoing clinical trials REVIEW

J. Vansteenkiste, S. Declerck, 2013 .

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.

J. Vansteenkiste, I. Wauters, L. Decoster, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The seventh tumor, node, metastasis staging system and lung cancer treatment choices: a matter of would, could, and should.

F. Shepherd, J. Vansteenkiste, 2010, Journal of Thoracic Oncology.

Chapter 8 – Positron Emission Tomography Imaging

C. Dooms, J. Vansteenkiste, C. Deroose, 2012 .

The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer.

Johan Vansteenkiste, Christophe Dooms, C. Dooms, 2004, The oncologist.

Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group.

K. Nackaerts, J. Vansteenkiste, M. Demedts, 1997, The Annals of thoracic surgery.

An unexpected abdominal 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) in a patient with limited stage small cell lung cancer.

K. Nackaerts, J. Vansteenkiste, E. Verbeken, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

R. Ramlau, J. von Pawel, C. Eschbach, 2012, Oncology.

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.

Y. Humblet, J. Vansteenkiste, J. Wolf, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan.

J. Vansteenkiste, J. Verschakelen, P. D. De Leyn, 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

A. Warth, A. Marchetti, L. Bubendorf, 2019, Lung cancer.

Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).

P. Jänne, A. Shaw, L. Crinò, 2012 .

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.

J. Vansteenkiste, F. Barlesi, B. Besse, 2019, Lung Cancer.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

J. Milanowski, C. Gridelli, D. Atanackovic, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue

C. Dooms, K. Nackaerts, D. Lambrechts, 2018, Radiation Oncology.

Medical thoracoscopic lung biopsy in interstitial lung disease: a prospective study of biopsy quality.

J. Vansteenkiste, M. Demedts, M. Thomeer, 1999, The European respiratory journal.

PL-3 Results of the randomized international adjuvant lung cancer trial (IALT): Cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (PTS) with resected non-small cell lung cancer (NSCLC)

J. Pignon, R. Pirker, T. Ciuleanu, 2003 .

Will liquid biopsies become our fluid transition to personalized immunotherapy?

J. Vansteenkiste, E. Wauters, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib monotherapy in advanced non-small cell lung cancer (NSCLC): Experience from a large, Western community implementation study

K. Nackaerts, J. Canon, J. Vansteenkiste, 2006 .

Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Michael Wallace, Johan Vansteenkiste, G. Silvestri, 2007, Chest.

Is Esophageal Ultrasound-Guided Fine Needle Aspiration the Last Stop on the Road to Accurate Mediastinal Staging?

C. Dooms, J. Vansteenkiste, 2009, Respiration.

Esophageal ultrasound-controlled fine needle aspiration for staging of mediastinal lymph nodes in patients with resectable lung cancer: do we always see the reality?

C. Dooms, J. Vansteenkiste, P. D. De Leyn, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Johan Vansteenkiste, G. Scagliotti, Keunchil Park, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line therapeutic options in non-small-cell lung cancer.

J. Vansteenkiste, 2006, Lung cancer.

Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL).

J. Vansteenkiste, F. Blackhall, J. Raats, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer

K. Nackaerts, H. Wildiers, J. Vansteenkiste, 2017, Lung.

A practical guide to measure "all" malignant pleural mesothelioma tumors by modified RECIST criteria?

K. Nackaerts, J. Vansteenkiste, P. Nafteux, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial.

P. Jänne, A. Kohlmann, L. Crinò, 2016 .

A Th1/IFNg Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Bengt Bergman, Rodrigo Arriagada, Johan Vansteenkiste, 2004, The New England journal of medicine.

Immunotherapy in patients with early stage resectable nonsmall cell lung cancer

J. Vansteenkiste, K. Ghysen, 2019, Current opinion in oncology.

Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)

Keunchil Park, J. Yi, J. Mazières, 2016, Pneumologie.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

C. Dooms, N. Girard, H. Gietema, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Transcarinal nneedle aaspiration bbiopsy iin tthe sstaging of llung ccancer

J. Vansteenkiste, M. Demedts, G. Deneffe, 1994 .

Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects.

D. de Ruysscher, D. Ruysscher, J. Vansteenkiste, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review.

R. Paridaens, J. Vansteenkiste, J. Vansteenkiste, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.

S. Novello, J. Vansteenkiste, T. Čufer, 2019 .

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.

E. Cho, S. Ramalingam, J. Vansteenkiste, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S.

V. Torri, G. Scagliotti, M. Hetzel, 2008 .

Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): PRS-03

C. Obasaju, G. Scagliotti, J. von Pawel, 2007 .

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

E. Cho, S. Ramalingam, J. Vansteenkiste, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic lymphocytic alveolitis with migrating pulmonary infiltrates after localized chest wall irradiation.

R. Paridaens, J. Vansteenkiste, M. Demedts, 1998, Acta clinica Belgica.

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer.

J. Vansteenkiste, D. Betticher, P. D. De Leyn, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Diagnostic tests of hyperventilation syndrome.

J. Vansteenkiste, M. Demedts, M. Demedts, 1991, The European respiratory journal.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

U. Dafni, D. de Ruysscher, D. Ruysscher, 2019, Lung cancer.

Three-year overall survival update from the PACIFIC trial.

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of Clinical Oncology.

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Yi-long Wu, D. Planchard, C. Faivre-Finn, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hormonal treatment in advanced non-small cell lung cancer: fact or fiction?

E. Wouters, J. Vansteenkiste, M. Demedts, 1996, The European respiratory journal.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

Yi-long Wu, D. Planchard, C. Faivre-Finn, 2021 .

A Th1/IFN g Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non – Small Cell Lung Cancer A

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.

C. Faivre-Finn, J. Vansteenkiste, J. Naidoo, 2022, Lung cancer.

Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.

Keunchil Park, F. de Marinis, M. Krzakowski, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration.

S. Novello, J. Vansteenkiste, T. Čufer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis

J. Vansteenkiste, 2017, ESMO Open.

C. Dooms, K. Nackaerts, K. Laere, 2022, EJNMMI Research.

Pharmacotherapy of chemotherapy-induced anaemia

J. Vansteenkiste, 2003, Expert opinion on pharmacotherapy.

Adult respiratory distress syndrome in neutropenic leukemia patients

J. Vansteenkiste, M. Boogaerts, 1989, Blut.

An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates.

Huanming Yang, Jian Wang, L. Bolund, 2020, Cancer cell.

Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.

J. Vansteenkiste, J. Glaspy, G. Rossi, 2002, Oncology.

A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer

R. Pirker, J. Vansteenkiste, J. Musil, 2001 .

Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.

J. Vansteenkiste, 2006, Cancer treatment reviews.

The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

J. Vansteenkiste, I. Wauters, 2005, Expert opinion on pharmacotherapy.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

H. Groen, T. Overbeck, Michael Thomas, 2020, The New England journal of medicine.

Fatal pulmonary veno-occlusive disease possibly related to gemcitabine.

K. Nackaerts, J. Vansteenkiste, M. Demedts, 2001, Lung cancer.

J. Vansteenkiste, J. Lester, C. Chouaid, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer

G. Giaccone, E. Smit, Y. Nishiwaki, 2003 .

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

T. Treasure, J. Jassem, J. Vansteenkiste, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2012 .

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

H. Groen, E. Smit, R. Heist, 2019, Journal of Clinical Oncology.

Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?

J. Vansteenkiste, E. Wauters, 2014, Journal of thoracic disease.

Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group.

P. Dupont, J. Vansteenkiste, S. Stroobants, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

D. Planchard, C. Faivre-Finn, S. Senan, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent

R. Pirker, J. Vansteenkiste, H. Collins, 2012, Supportive Care in Cancer.

Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals

J. Vansteenkiste, I. Wauters, 2007, Expert review of anticancer therapy.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Original article Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: A multi-centre phase II study

J. Vansteenkiste, C. Manegold, A. Hanauske, 2004 .

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2018, The New England journal of medicine.

Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).

U. Dafni, D. de Ruysscher, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P3.02c-087 The Relationship of TILs and PD-L1 Expression in NSCLC Adenocarcinoma in Little to Non-Smokers with Driver Mutations and Outcome Parameters: Topic: IT Biomarkers

R. Salgado, K. Willard-Gallo, J. Vansteenkiste, 2017 .

Cost–utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer

C. Dooms, J. Vansteenkiste, Y. Lievens, 2006, European Respiratory Journal.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Keunchil Park, F. de Marinis, M. Krzakowski, 2018, The Lancet. Oncology.

Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors

A. Shaw, E. Felip, A. Santoro, 2012 .

First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.

A. Shaw, E. Felip, A. Santoro, 2012 .

A fatal case of cholestatic liver failure probably related to gemcitabine.

K. Nackaerts, J. Vansteenkiste, M. Demedts, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.

A. Kohlmann, S. Ramalingam, J. Vansteenkiste, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group.

K. Nackaerts, P. Dupont, L. Mortelmans, 1997, Chest.

CARDIO-THORACIC SURGERY

C. Dooms, J. Vansteenkiste, T. Lerut, 2009 .

Metabolic-structural concordance in paraneoplastic limbic encephalitis

W. van Paesschen, K. Van Laere, K. Goffin, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion

C. Dooms, D. de Ruysscher, A. Dingemans, 2018, Journal of Thoracic Oncology.

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells

Benjamin P. C. Chen, B. Faubert, R. Deberardinis, 2017, Nature.

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2018, Journal of Thoracic Oncology.

Early versus late chest radiotherapy for limited stage small cell lung cancer.

P. Lambin, D. de Ruysscher, D. Ruysscher, 2004, The Cochrane database of systematic reviews.

Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia

J. Vansteenkiste, M. Foote, G. Rossi, 2003, Expert opinion on biological therapy.

Pulmonary metastases of a tibia adamantinoma. Case report and review of the literature.

K. P. Van de Woestijne, J. Vansteenkiste, F. de Keyser, 1990, Acta clinica Belgica.

Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.

Serafino Pantano, Michael Thomas, A. Shaw, 2016 .

Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial.

C. Dooms, A. Nicholson, K. Rabe, 2010, JAMA.

Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.

J. Vansteenkiste, N. Thatcher, H. Mellstedt, 2011, Lung cancer.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Keunchil Park, J. Yi, J. Mazières, 2016, The Lancet.

Hematopoietic Growth Factors in Lung Cancer

C. Dooms, J. Vansteenkiste, 2004 .

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

M. Fiegl, R. Pirker, J. Vansteenkiste, 2002, Journal of the National Cancer Institute.

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.

K. Nackaerts, Y. Humblet, J. Vansteenkiste, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

S. Peters, S. Senan, D. Tan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, The New England journal of medicine.

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer

O. De Wever, I. Umelo, J. Vansteenkiste, 2015, Oncotarget.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

J. Canon, J. Vansteenkiste, P. Vuylsteke, 2015, Lung cancer.

Phenotype molding of stromal cells in the lung tumor microenvironment

P. Carmeliet, S. Aerts, D. Lambrechts, 2018, Nature Medicine.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D. de Ruysscher, D. Ruysscher, S. Peters, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

M. Ahn, Yi-long Wu, E. Felip, 2018, Journal of Clinical Oncology.

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

P. Jänne, J. Mazières, J. Vansteenkiste, 2021, JTO clinical and research reports.

Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Clinical lung cancer.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors in nonsmall cell lung cancer

G. Verleden, B. Jeremic, G. Fontanini, 2002 .

Capmatinib for the treatment of non-small cell lung cancer

J. Vansteenkiste, E. Wauters, P. Van Mol, 2019, Expert review of anticancer therapy.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

P. Jänne, A. Kohlmann, L. Crinò, 2017, JAMA.

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

E. Van Cutsem, J. Vansteenkiste, P. Schöffski, 2008, Investigational New Drugs.

The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema

J Verschakelen, M. Decramer, D. Lambrechts, 2011, European Respiratory Journal.

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

J. Vansteenkiste, N. Thatcher, R. Rosso, 1999, British Journal of Cancer.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Moon Soo Kim, N. Altorki, P. Therasse, 2016, The Lancet. Oncology.

PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study

N. Rizvi, J. Mazières, J. Vansteenkiste, 2017 .

Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.

J. Vansteenkiste, E. Wauters, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of denosumab in a patient with non-small-cell lung cancer and severe renal function impairment.

J. Vansteenkiste, E. Govaerts, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis

C. Dooms, K. Nackaerts, D. Lambrechts, 2022, Journal for ImmunoTherapy of Cancer.

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

J. V. van Meerbeeck, J. Canon, Y. Humblet, 2016, PloS one.

Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations

C. Dooms, J. Vansteenkiste, P. Vandenberghe, 2015, Diagnostic Pathology.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2019, Future oncology.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.

C. Dooms, D. de Ruysscher, S. Novello, 2019, European journal of cancer.

Lung cancer: diagnosis and staging

J. Vansteenkiste, G. Deslypere, Dorothée Gullentops, 2019, ERS Handbook Respiratory Medicine.

Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?

J. Vansteenkiste, E. Wauters, G. Deslypere, 2018, Therapeutic advances in medical oncology.

Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding.

J. Vansteenkiste, E. Wauters, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

G. Scagliotti, F. Shepherd, J. Vansteenkiste, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience.

C. Dooms, K. Nackaerts, S. Dymarkowski, 2012, Radiology.

The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, N. Girard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Oudkerk, S Senan, M. Oudkerk, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer.

P. Lambin, D. de Ruysscher, D. Ruysscher, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized

N. Altorki, S. Thongprasert, J. Vansteenkiste, 2009 .

Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC)

Jamila Louahed, Marcin Zieliński, Vincent Brichard, 2008 .

Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging.

C. Dooms, K. Nackaerts, S. Dymarkowski, 2015, Radiology.

Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study.

J. von Pawel, U. Gatzemeier, J. Vansteenkiste, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification

J. Austin, A. Nicholson, I. Petersen, 2009 .

Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.

Serafino Pantano, B. Solomon, D. Camidge, 2021, Lung Cancer.

Suitability of Small Bronchoscopic Tumour Specimens for Lung Cancer Genotyping

C. Dooms, K. Nackaerts, V. Ninane, 2014, Respiration.

Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.

J. Vansteenkiste, 2014, Future oncology.

Targeting the immune system for management of NSCLC: the revival?

J. Vansteenkiste, J. Brahmer, M. Reck, 2013, Current Respiratory Care Reports.

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

M. Socinski, M. Edelman, J. Vansteenkiste, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model

B. Solomon, J. Wolf, S. Dimitrijević, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

G. Scagliotti, Keunchil Park, F. de Marinis, 2010, Lung cancer.

Gefitinib (Iressa®): a novel treatment for non-small cell lung cancer

J. Vansteenkiste, 2004, Expert review of anticancer therapy.

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

J. Milanowski, J. Strausz, R. Ramlau, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2003, Lung cancer.

Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.

D. de Ruysscher, D. Ruysscher, J. Vansteenkiste, 1998, Lung Cancer.

Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.

K. Nackaerts, J. Vansteenkiste, M. Demedts, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.

J. Vansteenkiste, H. Ulrichts, R. Deman, 1995, Lung cancer.

Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: how CONSORTed are the data?

C. Dooms, J. Vansteenkiste, K. Pat, 2008, Lung cancer.

The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer

C. Dooms, J. Vansteenkiste, K. Pat, 2006, Expert review of anticancer therapy.

Treatment of patients with advanced non-small cell lung cancer

C. Dooms, J. Vansteenkiste, 2004 .

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.

J. Tabernero, F. Ciardiello, T. Seufferlein, 2016, The oncologist.

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.

Keunchil Park, J. Vansteenkiste, J. Yang, 2021, Lung cancer.

Identification of a novel HER 3 activating mutation homologous to EGFR-L 858 R in lung cancer

J. Vansteenkiste, E. Teugels, C. Geers, 2016 .

Lung cancer at the intensive care unit: The era of targeted therapy.

C. Dooms, J. Vansteenkiste, V. Adam, 2015, Lung cancer.

How Do We Move Forward with Vaccines in Lung Cancer

J. Vansteenkiste, A. Ottevaere, N. Brucker, 2015 .

2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease

C. Dooms, A. Marchetti, L. Bubendorf, 2014 .

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

C. Gridelli, F. Hirsch, V. Georgoulias, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Generalized or personalized treatment for stage IIIA-N2 non-small-cell lung cancer?

C. Dooms, J. Vansteenkiste, V. Van Damme, 2010, Expert opinion on pharmacotherapy.

A Randomized Clinical Trial of Flex 19G Needles versus 22G Needles for Endobronchial Ultrasonography in Suspected Lung Cancer

C. Dooms, K. Nackaerts, B. Weynand, 2018, Respiration.

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

C. Dooms, K. Nackaerts, T. Roskams, 2014, Translational Respiratory Medicine.

Vaccination therapy for non-small-cell lung cancer

K. Cuppens, J. Vansteenkiste, 2014, Current opinion in oncology.

Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification

A. Nicholson, G. Scagliotti, W. Travis, 2011, European Respiratory Journal.

DNA methylation profiling of non-small cell lung cancer reveals a COPD-driven immune-related signature

M. Decramer, D. Lambrechts, W. Janssens, 2015, Thorax.

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Johan Vansteenkiste, J. von Pawel, J. Vansteenkiste, 2009, Investigational New Drugs.

RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue

C. Dooms, K. Nackaerts, D. Lambrechts, 2018, Radiation oncology.

Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer

J. Vansteenkiste, T. Lerut, Y. Lievens, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?

J. Vansteenkiste, I. Wauters, A. Sibille, 2012, Expert review of anticancer therapy.

Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.

V. Torri, G. Scagliotti, M. Hetzel, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer: Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop

S. Schoenberg, C. Fink, P. Apfaltrer, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)

J. Jassem, E. Esteban, J. Vansteenkiste, 2007 .

Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

C. Dooms, J. Mortensen, J. Vansteenkiste, 2004, The Lancet. Oncology.

Lung cancer: Progress in diagnosis, staging and therapy

N. Tanner, G. Silvestri, R. Pirker, 2010, Respirology.

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

P. Jänne, A. Shaw, L. Crinò, 2015, British Journal of Cancer.

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

R. Govindan, H. Choy, T. Mok, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer.

P. Lambin, L. Boersma, D. de Ruysscher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer

P. Lambin, D. Ruysscher, J. Vansteenkiste, 2004 .

Screening and early detection of lung cancer.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Addressing the unmet need in lung cancer: The potential of immuno-oncology.

G. Scagliotti, J. Vansteenkiste, P. Bironzo, 2015, Cancer treatment reviews.

Thoracic oncology in Europe: the ERS action plan by the Thoracic Oncology Assembly

J. Vansteenkiste, J. Sculier, A. Scherpereel, 2010, European Respiratory Journal.

Early Stage Lung Cancer: Progress in the Last 40 Years

D. Carbone, H. Asamura, S. Novello, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

S Senan, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus Conference on Lung Cancer : early-stage non-small-cell lung cancer consensus on diagnosis , treatment and follow-up

C. Dooms, G. Veronesi, R. Stahel, 2014 .

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.

C. Schumann, I. Zuna, M. Kreuter, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol

H. Dienemann, Michael Thomas, M. Kreuter, 2007, BMC Cancer.

Prospects and progress of atezolizumab in non-small cell lung cancer

Keunchil Park, J. Vansteenkiste, E. Wauters, 2017, Expert opinion on biological therapy.

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.

G. Scagliotti, J. von Pawel, J. Vansteenkiste, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer.

G. Scagliotti, W. De Neve, J. V. van Meerbeeck, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III‐N2 NSCLC after Induction Chemotherapy and Resection

C. Dooms, D. de Ruysscher, P. Bulens, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?

D. de Ruysscher, J. Vansteenkiste, J. Belderbos, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC).

H. Groen, E. Smit, R. Heist, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. van Houwelingen, J. Kirkwood, 2019, Clinical Cancer Research.

Evaluation of NGS and RT‐PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

C. Dooms, K. Nackaerts, A. Warth, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Second primary lung cancer in Flanders: frequency, clinical presentation, treatment and prognosis.

M. Noppen, J. Tasson, G. Joos, 1996, Lung cancer.

Characteristics and outcome of unplanned hospital admissions in patients with lung cancer: a longitudinal tertiary center study. Towards a strategy to reduce the burden

K. Cuppens, J. Vansteenkiste, W. Sermeus, 2016, Supportive Care in Cancer.

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

J. Canon, G. Bodoky, J. Vansteenkiste, 2006, Journal of the National Cancer Institute.

Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC).

J. Jassem, J. Vansteenkiste, B. Passlick, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET scan in lung cancer: current recommendations and innovation.

J. Vansteenkiste, S. Stroobants, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Positron emission tomography in the management of non-small cell lung cancer.

J. Vansteenkiste, S. Stroobants, 2004, Hematology/oncology clinics of North America.

Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases

K. Nackaerts, J. Vansteenkiste, M. Demedts, 1997 .

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

A. Santoro, J. von Pawel, L. Paz-Ares, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018, The New England journal of medicine.

Is central lung tumour location really predictive for occult mediastinal nodal disease in (suspected) non-small-cell lung cancer staged cN0 on 18F-fluorodeoxyglucose positron emission tomography–computed tomography?

C. Dooms, K. Nackaerts, D. de Ruysscher, 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

O-3 Randomized phase II study of the novel tubulin targetin agent, BMS-247550 (Epothilone B analogue) in the treatment of non-small cell lung cancer (NSCLC) in patients (pts) who have failed first line platinum containing therapy

M. Edelman, L. Paz-Ares, J. Vansteenkiste, 2003 .

Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.

A. Shaw, E. Felip, F. D. De Braud, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History

R. Salgado, G. G. Van den Eynden, K. Willard-Gallo, 2019, Pathology & Oncology Research.

Postoperative radiotherapy for lung cancer: Is it worth the controversy?

D. Ruysscher, S. Peeters, J. Vansteenkiste, 2016, Cancer treatment reviews.

Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.

P. Lambin, D. de Ruysscher, J. Vansteenkiste, 2007, Cancer treatment reviews.

Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer - A prospective analysis of 50 cases

K. Nackaerts, P. Dupont, L. Mortelmans, 1997 .

Survival after resection of synchronous bilateral lung cancer.

J. Vansteenkiste, T. Lerut, H. Decaluwé, 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

An unusual cause of Dysphagia in a 76-year-old heavy smoker.

J. Vansteenkiste, E. Verbeken, P. Nafteux, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?

C. Dooms, P. Adriaensens, J. Vansteenkiste, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2017 .

Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study

K. Nackaerts, J. Canon, J. Vansteenkiste, 2006, European Respiratory Journal.

Pulmonary carcinoid: a rare thoracic malignancy, a high need for better defined systemic therapy.

J. Vansteenkiste, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Corrigendum to “Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis” [Radiother Oncol 110 (2014) 3–8]

C. Dooms, K. Haustermans, D. Ruysscher, 2014 .

Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis.

C. Dooms, K. Haustermans, D. de Ruysscher, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

M. Aristides, G. Scagliotti, C. Gridelli, 2005, Lung cancer.

The future of adjuvant chemotherapy for resected non-small cell lung cancer

J. Vansteenkiste, R. Schildermans, 2005, Expert review of anticancer therapy.

Maintenance Therapy for Advanced Non–Small-Cell Lung Cancer: A Pilot Study on Patients’ Perceptions

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial.

G. Giaccone, L. Spaggiari, J. Vansteenkiste, 2019, European journal of cancer.

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

A. Marchetti, L. Bubendorf, U. Dafni, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.

U. Dafni, D. Ruysscher, R. Stahel, 2018 .

The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer

Sigrid Stroobants, Philippe Lambin, Cary Dehing-Oberije, 2007 .

Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy.

J. Vansteenkiste, G. Deneffe, T. Lerut, 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Y. Ohe, B. Chewaskulyong, E. Cho, 2017 .

Reply to “On Plain Language and Going Astray”

F. Shepherd, J. Vansteenkiste, 2011 .

Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

Karen So, J. Vansteenkiste, P. Dickinson, 2018, British journal of clinical pharmacology.

The European initiative for quality management in lung cancer care

Erik Jakobsen, Corinne Faivre-Finn, Dirk De Ruysscher, 2014, European Respiratory Journal.

Clinical factors predictive of long-term survival in advanced non-small cell lung cancer.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2013, Lung cancer.

Induction treatment before surgery for non-small cell lung cancer.

R. Mirimanoff, J. Pignon, A. Gregor, 2003, Lung cancer.

Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer

C. Dooms, M. Socinski, F. Detterbeck, 2015 .

Positron emission tomography in nonsmall cell lung cancer

C. Dooms, J. Vansteenkiste, 2007, Current opinion in pulmonary medicine.

Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer.

C. Dooms, M. Socinski, F. Detterbeck, 2004, Chest.

Value of FDG-PET in the management of non-small cell lung cancer.

J. Vansteenkiste, J. Verschakelen, S. Stroobants, 2003, European journal of radiology.

Imaging in lung cancer: positron emission tomography scan

J. Vansteenkiste, 2002, European Respiratory Journal.

The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.

J. Vansteenkiste, S. Stroobants, S. Stroobants, 2001, The European respiratory journal.

Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. The Leuven Lung Cancer Group.

J. Menten, J. Vansteenkiste, M. Demedts, 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography.

A. Lammertsma, O. Hoekstra, E. Smit, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors.

H. Gietema, H. Aerts, A. Dekker, 2023, European journal of cancer.

Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma

C. Dooms, P. Adriaensens, Z. Shkedy, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Positron emission tomography in nonsmall cell lung cancer

C. Dooms, J. Vansteenkiste, 2007, Current opinion in oncology.

FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.

J. Vansteenkiste, 2005, Lung cancer.

Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer.

C. Dooms, P. Dupont, L. Mortelmans, 2003, Clinical lung cancer.

FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases?

F. Maes, J. Bogaert, J. Nuyts, 1998, European Journal of Nuclear Medicine.

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.

Keunchil Park, J. Yi, J. Mazières, 2016 .

Prognostic I mportance o f t he S tandardized U ptake V alue o n 18 F-Fluoro-2-Deoxy-Glucose-Positron E mission T omography Scan i n N on-Small-Cell L ung C ancer: An A nalysis o f 1 25 C ases

Patrick Dupont, Luc Mortelmans, Sigrid Stroobants, 1999 .

ORA cover sheet

M. Edelman, J. Vansteenkiste, J. Douillard, 2018 .

LBA78 A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden

C. Dooms, K. Nackaerts, D. Lambrechts, 2020, Annals of Oncology.

FDG-PET in the Locoregional Lymph Node Staging of Non-small Cell Lung Cancer. A Comprehensive Review of the Leuven Lung Cancer Group Experience.

L. Mortelmans, J. Vansteenkiste, 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

Review article Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review

J. Menten, J. Vansteenkiste, M. Demedts, 1998 .

Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).

A. Shaw, E. Felip, D. Tan, 2017 .

Endobronchial Ultrasonography in Bronchoscopic Occult Pulmonary Lesions

C. Dooms, H. Becker, J. Vansteenkiste, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)

C. Faivre-Finn, J. Vansteenkiste, P. Dennis, 2019, Annals of Oncology.

P8 Screening for a geriatric risk profile in older cancer patients: a comparative study of the predictive validity of three screening tools

H. Wildiers, I. Vergote, J. Vansteenkiste, 2009 .

Abstract CT082: Capmatinib inMETex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRYmono-1study, including efficacy in patients (pts) with brain metastases (BM)

H. Groen, E. Smit, R. Heist, 2020 .

Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic non-squamous cell NSCLC.

J. Vansteenkiste, T. van Gelder, R. Cornelissen, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials

T. Lynch, F. Shepherd, R. Pirker, 2009 .

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

K. O'Byrne, T. Lynch, F. Shepherd, 2014, Lung cancer.

Treatment of unresectable stage III NSCLC: Real world cohort study and literature review.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2023, Cancer treatment and research communications.

Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.

C. Dooms, B. Weynand, J. Vansteenkiste, 2022, Lung cancer.

Association Between 18F-Fluoro-2-Deoxy-d-Glucose Uptake Values and Tumor Vitality: Prognostic Value of Positron Emission Tomography in Early-Stage Non-small Cell Lung Cancer

C. Dooms, D. de Ruysscher, J. Vansteenkiste, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.

Keunchil Park, O. Burghuber, Yuh-Min Chen, 2023, Future oncology.

The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.

G J Kutcher, D. Huyskens, L. Vanuytsel, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

O-239 Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data

G. Scagliotti, J. Vansteenkiste, J. Schiller, 2003 .

Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.

J. Engelman, A. Shaw, E. Felip, 2013 .

Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial

U. Dafni, D. Ruysscher, R. Stahel, 2019, Annals of Oncology.

The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.

Philippe Lambin, Cary Dehing-Oberije, Dirk De Ruysscher, 2007, European journal of cancer.

Pre-operative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage nonsmall cell lung cancer

Johan Vansteenkiste, Sofie Derijcke, J. Vansteenkiste, 2010 .

Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer

J. Vansteenkiste, P. Zatloukal, N. Dohollou, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data

R. Rami-Porta, R. Govindan, J. Lafitte, 2015, European Respiratory Journal.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.

J. Canon, J. Vansteenkiste, Yali Fu, 2013 .

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from the phase 1 , multicentre , open-label ASCEND-1 trial

Michael Thomas, A. Shaw, Gregory Riely, 2016 .

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Johan Vansteenkiste, Johan Vansteenkiste, Sofie Derijcke, 2009 .

OA 05.02 Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis

S. Ramalingam, J. Vansteenkiste, I. Okamoto, 2017 .

Three-year overall survival update from the PACIFIC trial

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Annals of Oncology.

MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR)

J. Mazières, J. Vansteenkiste, L. Fehrenbacher, 2017 .

Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease).

J. Vansteenkiste, G. Deneffe, T. Lerut, 1996, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

D. Planchard, C. Faivre-Finn, S. Senan, 2020 .

Surgical treatment of small cell lung cancer.

J. Vansteenkiste, M. Demedts, G. Deneffe, 1995, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR)

J. Mazières, J. Vansteenkiste, L. Fehrenbacher, 2018 .

PET scan in the staging of non-small cell lung cancer.

J. Vansteenkiste, 2003, Lung Cancer.

Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.

R. Pirker, J. Vansteenkiste, M. Hedenus, 2016, Clinical therapeutics.

A rare central thoracic tumor.

R. Sciot, K. Cuppens, M. Debiec‐Rychter, 2014, Journal of Thoracic Oncology.

Nodules, CT-scans and PET-scans: a good partnership.

J. Vansteenkiste, 2004, Lung cancer.

Evaluation of the clinical usefulness of capnography curves during a hyperventilation provocation test in the diagnosis of hyperventilation syndrome.

J. Vansteenkiste, M. Demedts, F. Rochette, 1991, Acta clinica Belgica.

CHEMOTHERAPY (CT) PLUS CETUXIMAB AS 1ST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): META-ANALYSIS OF INDIVIDUAL PATIENT DATA

T. Lynch, F. Shepherd, R. Pirker, 2010 .

Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study

Ying Cheng, Keunchil Park, R. Ramlau, 2019, AntiCancer Research.

Mediastinal emphysema and small cell lung cancer (SCLC): a case-report.

K. Nackaerts, J. Vansteenkiste, E. Verbeken, 2005, Lung cancer.

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018 .

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

C. Dooms, A. Marchetti, K. Syrigos, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

C. Dooms, A. Marchetti, L. Bubendorf, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Transcarinal needle aspiration biopsy in the staging of lung cancer.

J. Vansteenkiste, M. Demedts, G. Deneffe, 1994, The European respiratory journal.

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

P Baas, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Early versus late chest radiotherapy for limited stage small cell lung cancer: a systematic review and meta-analysis

P. Lambin, D. Ruysscher, J. Vansteenkiste, 2004 .

Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data

J. V. van Meerbeeck, J. Vansteenkiste, Tine Cuppens, 2020, Acta clinica Belgica.

Reflections on the current staging system for lung cancer

G. Verleden, B. Jeremic, G. Fontanini, 2002 .

836 Detection of N2-disease in potentially operable non-small cell lung cancer with FDG-PET scan: A prospective study

K. Nackaerts, J. Bogaert, P. Dupont, 1997 .

Practical approach to patients presenting with multiple synchronous suspect lung lesions. A reflection on the current TNM classification based on 54 cases with complete follow-up

K. Nackaerts, J. Vansteenkiste, M. Demedts, 2001 .

Staging of Lung Cancer.

C. Dooms, J. Vansteenkiste, S. Stroobants, 2006, PET clinics.

Prevalence and clinical association of MET gene amplification in patients with NSCLC: results from the ETOP lungscape project

A. Warth, H. Dienemann, A. Marchetti, 2015 .

Author Correction: CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells

Benjamin P. C. Chen, B. Faubert, R. Deberardinis, 2019, Nature.

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA

A. Kohlmann, S. Ramalingam, J. Vansteenkiste, 2020, Journal of Thoracic Oncology.

Characterisation of solitary pulmonary lesions combining visual perfusion and quantitative diffusion MR imaging

C. Dooms, K. Nackaerts, S. Dymarkowski, 2014, European Radiology.

Immunotherapy for lung cancer: ongoing clinical trials.

J. Vansteenkiste, S. Declerck, 2014, Future oncology.

ES01.01 Chemotherapy is Strictly Additive to Immunotherapy

J. Vansteenkiste, E. Wauters, 2019, Journal of Thoracic Oncology.

First-line treatment patterns in advanced NSCLC in western Europe (EU), the United States, and Japan including a comparative analysis of younger versus elderly patients.

J. Vansteenkiste, M. Koester, C. Eschbach, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-celltranscriptomicsidentifies pathogenic T-helper 17.1 cells and pro-inflammatorymonocytesinimmune checkpoint inhibitor-related pneumonitis

C. Dooms, K. Nackaerts, D. Lambrechts, 2022 .

Abstract A37: Identification of a gene expression signature predictive of clinical activity following MAGE‐A3 ASCI treatment

J. Vansteenkiste, B. Dizier, Fernando Ulloa-Montoya, 2009 .

R. Govindan, H. Choy, T. Mok, 2016, Journal of Clinical Oncology.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

J. Austin, I. Petersen, V. Rusch, 2011, Journal of Thoracic Oncology.

Phenotype molding of stromal cells in the lung tumor microenvironment

P. Carmeliet, S. Aerts, D. Lambrechts, 2018, Nature Medicine.

The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.

C. Dooms, K. Nackaerts, B. Weynand, 2016, Lung cancer.

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

J. Crowley, G. Giaccone, A. Nicholson, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

9004 Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

J. Vansteenkiste, F. Blackhall, J. Raats, 2009 .

Staging of Lung Cancer.

R. M. Peters, C. Dooms, J. Vansteenkiste, 2006, PET clinics.

Ask the expert: Thoracic oncology

J. Vansteenkiste, 2010 .

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer

J. Vansteenkiste, T. Lerut, Y. Lievens, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

REPORT ASCO 2000 NEW ORLEANS : LUNG CANCER

J. Vansteenkiste, 2005 .

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and 1 rosuvastatin 2

J. Vansteenkiste, K. Vishwanathan, D. Weilert, 2019 .

Broncholithiasis: rare but still present.

J. Vansteenkiste, M. Demedts, A. Nollet, 1998, Respiratory medicine.

Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study.

K. Nackaerts, D. de Ruysscher, J. Vansteenkiste, 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Non-small cell lung cancer, early stage

L. Bubendorf, T. Yamanaka, M. Okada, 2012 .

Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.

Karen So, J. Vansteenkiste, P. Dickinson, 2016 .

B. Solomon, J. Wolf, S. Dimitrijević, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes Link

C. Dooms, D. Ruysscher, P. Bulens, 2017 .